MedTrace Logo

Probiotics in IgA Nephropathy

NCT01781312 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-01-31

No results posted yet for this study

Summary

Recent studies have shown an increased gastrointestinal reactivity and increased intestinal permeability in IgA nephropathy (IgAN). Probiotic supplementation is known to impact the gastrointestinal immune system possibly by improvement of both the immunologic and the non-immunologic intestinal barrier. Probiotic supplementation should thus theoretically have an effect on IgAN. In this study the investigators will study the efficacy and safety of Lactobacillus reuteri.

Conditions

Interventions

DIETARY_SUPPLEMENT

ProTectis

DIETARY_SUPPLEMENT

Gastrus

Sponsors & Collaborators

  • University Hospital, Linkoeping

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • Uppsala University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-07-31
Completion
2014-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01781312 on ClinicalTrials.gov